On November 20, 2023, Arcus Biosciences Inc (NYSE: RCUS) opened at $14.61, lower -3.66% from the last session. During the day, the shares moved up to $14.875 and dropped to $13.89 before settling in for the closing price of $14.49. Price fluctuations for RCUS have ranged from $12.95 to $36.13 over the past 52 weeks.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 262.14%. Company’s average yearly earnings per share was noted -9.29% at the time writing. With a float of $48.18 million, this company’s outstanding shares have now reached $72.90 million.
The extent of productivity of a business whose workforce counts for 500 workers is very important to gauge. In terms of profitability, gross margin is +87.50, operating margin of -250.00, and the pretax margin is -237.50.
Arcus Biosciences Inc (RCUS) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Arcus Biosciences Inc is 35.63%, while institutional ownership is 65.98%. The most recent insider transaction that took place on Sep 22, was worth 427,166. In this transaction Chief Operating Officer of this company sold 21,369 shares at a rate of $19.99, taking the stock ownership to the 302,691 shares. Before that another transaction happened on Jul 28, when Company’s Chief Operating Officer sold 45,000 for $20.25, making the entire transaction worth $911,250. This insider now owns 336,566 shares in total.
Arcus Biosciences Inc (RCUS) Performance Highlights and Predictions
This company achieved a net margin of -238.39 while generating a return on equity of -35.64. Wall Street market experts anticipate that the next fiscal year will bring earnings of 13.96 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.29% per share during the next fiscal year.
Arcus Biosciences Inc (NYSE: RCUS) Trading Performance Indicators
Check out the current performance indicators for Arcus Biosciences Inc (RCUS). In the past quarter, the stock posted a quick ratio of 4.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.00, a number that is poised to hit -1.04 in the next quarter and is forecasted to reach -4.08 in one year’s time.
Technical Analysis of Arcus Biosciences Inc (RCUS)
The latest stats from [Arcus Biosciences Inc, RCUS] show that its last 5-days average volume of 0.65 million was inferior to 0.97 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 30.42%. Additionally, its Average True Range was 0.94.
During the past 100 days, Arcus Biosciences Inc’s (RCUS) raw stochastic average was set at 8.07%, which indicates a significant decrease from 25.25% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 83.55% in the past 14 days, which was higher than the 64.39% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.76, while its 200-day Moving Average is $18.59. Now, the first resistance to watch is $14.59. This is followed by the second major resistance level at $15.23. The third major resistance level sits at $15.58. If the price goes on to break the first support level at $13.61, it is likely to go to the next support level at $13.26. Assuming the price breaks the second support level, the third support level stands at $12.62.
Arcus Biosciences Inc (NYSE: RCUS) Key Stats
There are currently 74,856K shares outstanding in the company with a market cap of 1.05 billion. Presently, the company’s annual sales total 112,000 K according to its annual income of -267,000 K. Last quarter, the company’s sales amounted to 32,000 K and its income totaled -71,000 K.